Key points are not available for this paper at this time.
Our data identify avibactam as the first efficient inhibitor of BlaMab and strongly suggest that β-lactamase inhibition should be evaluated to provide improved therapeutic options for M. abscessus infections.
Dubée et al. (Thu,) studied this question.